Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 6, 2003, Pages 2719-2725

  Meier, Juris J ^a   Gallwitz, Baptist ^a   Salmen, Stefan ^a   Goetze, Oliver ^a   Holst, Jens J ^b   Schmidt, Wolfgang E ^a   Nauck, Michael A ^a,c  

^a ST JOSEF HOSPITAL   (Germany)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Diabeteszentrum   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; OCTANOIC ACID;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DOSE RESPONSE; DRUG EFFECT; DRUG INFUSION; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; STOMACH EMPTYING;

EID: 0037667613     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-030049     Document Type: Article

References (41)

1. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W 1993 Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744
2. Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, Hufner M, Schmiegel WH 2002 Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion dnring hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 87:1239-1246
3. Nauck MA, Holst JJ, Willms B, Schmiegel W 1997 Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. Exp Clin Endocrinol Diabetes 105:187-195
4. Drucker DJ 2002 Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 122:531-544
5. Meier JJ, Gallwitz B, Schmidt WE, Nauck MA 2002 Glucagon-like peptide 1 (GLP-1) as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol 440:269-279
6. Åhren B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, Sandqvist. M, Bavenholm P, Efendic S, Eriksson JW, Dickinson S, Holmes D 2002 Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25:869-875
7. Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agerso H, Veldhuis J, Porksen N, Schmitz O 2002 Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 51:424-429
8. Zander M, Madsbad S, Madsen JL, Holst JJ 2002 Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830
9. Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC 1996 Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Diabetes 45:1524-1530
10. Larsen J, Hylleberg B, Ng K, Damsbo P 2001 Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care 24:1416-1421
11. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R 2001 Intensive insulin therapy in the critically ill patients. N Engl J Med 345:1359-1367
12. Nauck MA, Walberg J, Vethacke A, Holst JJ, Senkal M, Gallwitz B 2002 Reduction of hyperglycemia by intravenous GLP-1 in patients under parenteral nutrition [Abstract]. Diabetologia 45(Suppl 2):A672
13. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ 1993 Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38:665-673
14. Willms B, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, Nauck MA 1996 Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81:327-332
15. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH 1997 Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273:E981-E988
16. Schirra J, Kuwert P, Wank U, Leicht P, Arnold R, Goke B, Katschinski M 1997 Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men. Proc Assoc Am Physicians 109:84-97
17. Flint A, Raben A, Astrup A, Holst JJ 1998 Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101:515-520
18. Ritzel R, Ørskov C, Holst JJ, Nauck MA 1995 Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 38:720-725
19. Horowitz M, O'Donovan D, Jones KL, Feinle C, Rayner CK, Samsom M 2002 Gastric emptying in diabetes: clinical significance and treatment. Diabetic Med 19:177-194
20. Meneilly GS, McIntosh CH, Pederson RA, Habener JF, Gingerich R, Egan JM, Finegood DT, Elahi D 2001 Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes. Diabetes Care 24:1951-1956
21. Zander M, Taskiran M, Toft-Nielsen MB, Madsbad S, Holst JJ 2001 Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes. Diabetes Care 24:720-725
22. Gutzwiller J-P, Göke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, Winterhalder R, Conen D, Beglinger C 1999 Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 44:81-86
23. Meier JJ, Salmen S, Goetze O, Baller B, Holst JJ, Schmidt WE, Nauck MA, Gallwitz B 2002 Normalisation of fasting and postprandial blood glucose with graded doses of Glucagon-like peptide 1 (GLP-1) in type 2 diabetic patients [Abstract]. Diabetologia 45(Suppl 1):A671
24. Ghoos YF, Maes BD, Geypens BJ, Mys G, Hiele MI, Rutgeerts PJ, Vantrappen G 1993 Measurement of gastric emptying rate of solid meals by means of a carbon-labeled octanoic acid breath test. Gastroenterology 104:1640-1647
25. 13C]acetate breath test accurately reflects gastric emptying of liquids in both liquid and semisolid test meals. Gastroenterology 108:1048-1055
26. Meier JJ, Hücking K, Holst JJ, Deacon C, Schmiegel W, Nauck MA 2001 Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 50:2497-2504
27. Holst JJ 1982 Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin. Biochem J 207:381-388
28. Ørskov C, Rabenhej L, Wettergren A, Kofod H, JJH 1994 Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans. Diabetes 43:535-539
29. Polonsky KS, Given BD, Hirsch LJ, Tillil H, Shapiro ET, Beebe C, Frank BH, Galloway JA, Van Cauter E 1988 Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 318:1231-1239
30. Pratley RE, Weyer C 2001 The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia 44:929-945
31. Mitrakou A, Kelley D, Mokan M, Veneman T, Pangburn T, Reilly J, Gerich J 1992 Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 326:22-29
32. Unger RH, Aguilar-Parada E, Muller WA, Eisentraut AM 1970 Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest 49:837-848
33. Campbell IW, Heading RC, Tothill P, Buist TA, Ewing DJ, Clarke BF 1977 Gastric emptying in diabetic autonomic neuropathy. Gut 18:462-467
34. Ricci JA, Siddique R, Stewart WF, Sandler RS, Sloan S, Farup CE 2000 Upper gastrointestinal symptoms in a U.S. national sample of adults with diabetes. Scand J Gastroenterol 35:152-159
35. Horowitz M, Harding PE, Maddox AF, Wishart JM, Akkermans LM, Chatterton BE, Shearman DJ 1989 Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 32:151-159
36. 2-terminus in type 2-diabetic patients and in healthy subjects. Diabetes 44:1126-1131
37. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, Ghatei MA, Bloom SR 2001 Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol 281:E155-E161
38. Holst JJ, Deacon CF 1998 Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 47:1663-1670
39. Malmberg K 1997 Prospective randomised study of intensive treatment on long term survival after myocardial infarction in patients with diabetes mellitus: DIGAMI (Diabetes Mellitus, Insulin Glucose infusion in Acute Myocardial Infarction) Study Group. Br Med J 314:1512-1515
40. Carson JL, Scholz PM, Chen AY, Peterson ED, Gold J, Schneider SH 2002 Diabetes mellitus increases short-term mortality and morbidity in patients undergoing coronary artery bypass graft surgery. J Am Coll Cardiol 40:418-423
41. Bruno A, Levine SR, Frankel MR, Brott TG, Lin Y, Tilley BC, Lyden PD, Broderick JP, Kwiatkowski TG, Fineberg SE 2002 Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology 59:669-674